Earticle

초록

영어

Purpose: In this study, a microneedle patch (MNP) containing cannabidiol (CBD, YC-2106) was produced, and its efficacy was evaluated for human safety and the treatment of inflammatory diseases. Methods: First, MNPs containing 0%, 1%, and 3% cannabidiol were prepared. To evaluate the anti-inflammatory efficacy, a human skin tissue model (KeraSkin™) was purchased, the culture medium was collected 24 h and 48 h after MNP attachment, and the expression of interleukin-8 (IL-8) was compared and analyzed. A primary dermal irritation test was performed by requesting SGS certification in the United States, where an MNP was attached to 32 participants, and the attachment site was checked after 48 h and 96 h to confirm the occurrence of side effects. Results: No significant decrease in IL-8 expression was observed 24 h after lipopolysaccharide (LPS)-induced inflammation. However, after 48 h, IL-8 expression was significantly inhibited in the group treated with MNPs containing 1% and 3% CBD. In the primary dermal irritation test, no side effects were observed in any of the participants; therefore, safety was confirmed in the percutaneous phase. Conclusion: The CBD-MNP is effective in treating inflammatory diseases through the inhibition of IL-8 expression and exhibits high potential as a percutaneous drug for inflammatory treatment, which is safe for use in the human body.

한국어

목적: 본 연구에서는 대마유래 칸나비디올(CBD, YC-2106)을 포함하는 마이크로니들 패치(MNP)를 제작하고 염증성 질환 치료 효능과 인체 안전성을 평가하고자 하였다. 방법: 먼저 칸나비디올을 각각 0%, 1%, 3% 함유하는 마이크로니들 패치를 제작하였다. 항 염증 효능을 평가하기 위해 인체피부조직모델(KeraSkinTM)을 구입하였고, MNP 부착 24 h과 48 h 뒤에 배양액을 각각 수거하여 인 터루킨-8 (IL-8)의 발현을 비교분석하였다. 피부자극테스트는 미국 SGS사에 의뢰하여 수행하였고, 32명의 피험자에게 MNP를 부 착하고, 48 h과 96 h 뒤에 부착부위를 확인하여 부작용 발생여부를 확인하였다. 결과: LPS로 염증을 유발한 후 24 h 후에는 유의한 IL-8 발현 감소가 나타나지 않았지만, 48 h 후에는 CBD 1%와 3% 함유 MNP를 처리한 군에서 유의한 수준의 IL-8 발현 억제가 확 인되었다. 1차 피부자극테스트에서는 모든 피험자에서 부작용이 나타나지 않아 경피상에서 안전성을 확인하였다. 결론: 칸나비디 올 함유 마이크로니들 패치(CBD-MNP)는 IL-8 발현 억제를 통해 염증성 질환 치료 효능을 나타내며, 인체에 무해하기 때문에 경 피약물 염증치료제로서의 높은 잠재력을 나타내었다.

중국어

目的: 本研究制作了含有大麻二酚(cannabidiol, CBD，YC-2106)微针贴片(microneedle patch, MNP)，评估 了其对人体安全性和对炎症疾病的治疗效果。方法: 首先制备含0%、1%、3%大麻二酚的MNPs，为评价抗炎 效果，购买人体皮肤组织模型(KeraSkinTM)，MNP贴附后24 h、48 h，收集培养基，对比分析白细胞介素-8(IL- 8)表达情况。委托美国SGS认证机构进行单次皮肤刺激试验，32名受试者贴附MNP，48 h、96 h后检查贴附 部位，确认有无副作用发生。结果: 脂多糖(LPS)诱发炎症后24小时IL-8表达无明显下降，但48 h后，含1%和 3%CBD的MNPs组IL-8表达明显受到抑制。在单次皮肤刺激试验中，所有受试者均未观察到副作用，因此证实了 经皮阶段的安全性。结论: CBD-MNP通过抑制IL-8表达有效治疗炎症性疾病，作为经皮炎症治疗药物具有很高的 潜力，且在人体内使用是安全的。

목차

Abstract
Introduction
Methods
1. 칸나비디올(CBD)을 포함하는 마이크로니들 패치 제조
조직배양 및 시험물질 처리
3. 염증 관련 지표 확인방법
4. 피부자극테스트 개요
5. 통계처리
Results and Discussion
1. 마이크로니들 형성 여부 확인
2. 염증 관련 지표 확인결과
3. 피부자극테스트 결과
Conclusion
References
국문초록
참고문헌
中文摘要

키워드

저자

• Kun Hee Park [ 박건희 | Research Institute, Yuhan Care Co., Ltd, Hwaseong-si, Gyeonggi-do, Korea ]
• Aeri Song [ 송애리 | Research Institute, Yuhan Care Co., Ltd, Hwaseong-si, Gyeonggi-do, Korea ]
• Sinhwa Baek [ 백신화 | Research Institute, Yuhan Care Co., Ltd, Hwaseong-si, Gyeonggi-do, Korea ]
• Cho I Park [ 박초이 | Research Institute, Yuhan Care Co., Ltd, Hwaseong-si, Gyeonggi-do, Korea ]
• Sang Jin Park [ 박상진 | Research Institute, Endoderma Co., Ltd, Seongnam-si, Gyeonggi-do, Korea ]
• Hwanki Ho [ 호환기 | Research Institute, Endoderma Co., Ltd, Seongnam-si, Gyeonggi-do, Korea ]
• Kyung Mook Kang [ 강경묵 | Research Institute, Endoderma Co., Ltd, Seongnam-si, Gyeonggi-do, Korea ]
• Jeong Eun Lee [ 이정은 | Research Institute, Endoderma Co., Ltd, Seongnam-si, Gyeonggi-do, Korea ]
• Hyeon Ha Roh [ 노현하 | Research Institute, Endoderma Co., Ltd, Seongnam-si, Gyeonggi-do, Korea ]
• Jung Yeon Noh [ 노정연 | Research Institute, Endoderma Co., Ltd, Seongnam-si, Gyeonggi-do, Korea ]
• Hyun-Je Park [ 박현제 | Research Institute, Yuhan Care Co., Ltd, Hwaseong-si, Gyeonggi-do, Korea ] Corresponding Author

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  아시안뷰티화장품학술지 [Asian Journal of Beauty and Cosmetology]

• 간기

  계간

• pISSN

  2466-2046

• eISSN

  2466-2054

• 수록기간

  2016~2026

• 등재여부

  KCI 등재

• 십진분류

  KDC 593 DDC 646